钠-葡萄糖共转运蛋白2抑制剂调控心肌相关信号通路的研究进展

Research progress of sodium-glucose cotransporter 2 inhibitors in regulating myocardium related signaling pathways

钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂是近几年来倍受关注的口服降糖药物,其通过抑制肾脏近曲小管的葡萄糖重吸收有效控制血糖水平,还可以调节代谢并对心血管、肾脏起到独立保护作用。近年来研究发现,SGLT-2抑制剂可通过AMP活化蛋白激酶(AMPK)、活性氮氧化物(RONS)/信号转导及转录激活因子3(STAT3)、核因子E2相关因子2(Nrf2)/抗氧化反应元件(ARE)、转化生长因子(TGF)β/SMAD同源物(Smad)等信号通路改善心肌梗死、心肌纤维化等导致的心肌损伤,缓解心室重构,保护心脏。

Sodium-glucose cotransporter 2(SGLT-2)inhibitors are oral hypoglycemic drugs that have attracted much attention in recent years.SGLT-2 inhibitors can effectively control blood glucose levels by inhibiting glucose reabsorption in proximal convoluted tubules of the kidney,and it can also regulate metabolism and play an independent protective role in cardiovascular and renal diseases.Research in recent years has found that SGLT-2 inhibitors can activate signaling through AMP-activated protein kinase(AMPK),active nitrogen oxides(RONS)/signal transduction and transcription activator 3(STAT3),nuclear factor E2-associated factor 2(Nrf2)/antioxidant reaction element(ARE),and transforming growth factor(TGF)β/SMAD congeners(Smad)and other signaling pathways,which can improve myocardial damage caused by myocardial infarction and myocardial fibrosis,alleviate ventricular remodeling,and protect the heart.